[Pharmacoeconomic evaluation of use of ciprofloxacin and norfloxacin with cost-benefit analysis]. 2003

Armin Skrbo, and Aida Selava, and Lejla Zunić
Farmaceutski fakultet Univerziteta u Sarajevu.

Pharmacoeconomics is application of economical principles in health and pharmaceutical care sector. This is comparative analysis of treatment e.i. therapeutic alternatives (drugs), which takes into consideration both their costs and their health repercussions. Cost-benefit analysis (CBA) has been used where effectiveness of cost was calculated by calculating the sum of costs for urinary infections treatment which include the cost of examinations, the costs of therapy with ciprofloxacin and norfloksacin, other costs associated with treatment and total benefit for both of treatments. CBA of costs are pointing out that it is economically justified to prescribe both drugs, ciprofloxacin and norfloksacin, due the costs-benefit are the quite equal for both.

UI MeSH Term Description Entries
D009643 Norfloxacin A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE. AM-0715,AM-715,MK-0366,MK-366,MK0366,MK366,Noroxin,AM 0715,AM 715,AM0715,MK 0366,MK 366
D002939 Ciprofloxacin A broad-spectrum antimicrobial carboxyfluoroquinoline. Bay-09867,Ciprinol,Cipro,Ciprofloxacin Hydrochloride,Ciprofloxacin Hydrochloride Anhydrous,Ciprofloxacin Monohydrochloride Monohydrate,Anhydrous, Ciprofloxacin Hydrochloride,Bay 09867,Bay09867,Hydrochloride Anhydrous, Ciprofloxacin,Hydrochloride, Ciprofloxacin,Monohydrate, Ciprofloxacin Monohydrochloride,Monohydrochloride Monohydrate, Ciprofloxacin
D003362 Cost-Benefit Analysis A method of comparing the cost of a program with its expected benefits in dollars (or other currency). The benefit-to-cost ratio is a measure of total return expected per unit of money spent. This analysis generally excludes consideration of factors that are not measured ultimately in economic terms. In contrast a cost effectiveness in general compares cost with qualitative outcomes. Cost and Benefit,Cost-Benefit Data,Benefits and Costs,Cost Benefit,Cost Benefit Analysis,Cost-Utility Analysis,Costs and Benefits,Economic Evaluation,Marginal Analysis,Analyses, Cost Benefit,Analysis, Cost Benefit,Analysis, Cost-Benefit,Analysis, Cost-Utility,Analysis, Marginal,Benefit and Cost,Cost Benefit Analyses,Cost Benefit Data,Cost Utility Analysis,Cost-Benefit Analyses,Cost-Utility Analyses,Data, Cost-Benefit,Economic Evaluations,Evaluation, Economic,Marginal Analyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000890 Anti-Infective Agents Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. Anti-Infective Agent,Anti-Microbial Agent,Antimicrobial Agent,Microbicide,Microbicides,Anti-Microbial Agents,Antiinfective Agents,Antimicrobial Agents,Agent, Anti-Infective,Agent, Anti-Microbial,Agent, Antimicrobial,Agents, Anti-Infective,Agents, Anti-Microbial,Agents, Antiinfective,Agents, Antimicrobial,Anti Infective Agent,Anti Infective Agents,Anti Microbial Agent,Anti Microbial Agents
D014552 Urinary Tract Infections Inflammatory responses of the epithelium of the URINARY TRACT to microbial invasions. They are often bacterial infections with associated BACTERIURIA and PYURIA. Infection, Urinary Tract,Infections, Urinary Tract,Tract Infection, Urinary,Tract Infections, Urinary,Urinary Tract Infection
D017522 Bosnia and Herzegovina A country of eastern Europe, formerly the province of Bosnia in Yugoslavia, uniting with the province of Herzegovina to form the Republic of Bosnia and Herzegovina in 1946. It was created 7 April 1992 as a result of the division of Yugoslavia and recognized by the United States as an independent state. Bosnia takes is name from the river Bosna, in turn from the Indoeuropean root bhog, "current"; Herzegovina is from the Serbian herceg (duke) + -ov (the possessive) + -ina (country or territory). Bosnia and Hercegovina,Bosnia-Herzegovina,Bosnia

Related Publications

Armin Skrbo, and Aida Selava, and Lejla Zunić
January 1992, Terapevticheskii arkhiv,
Armin Skrbo, and Aida Selava, and Lejla Zunić
May 1993, PharmacoEconomics,
Armin Skrbo, and Aida Selava, and Lejla Zunić
February 1989, Atencion primaria,
Armin Skrbo, and Aida Selava, and Lejla Zunić
January 1991, Pharmacotherapy,
Armin Skrbo, and Aida Selava, and Lejla Zunić
January 1971, Scottish medical journal,
Armin Skrbo, and Aida Selava, and Lejla Zunić
January 1996, European journal of ophthalmology,
Armin Skrbo, and Aida Selava, and Lejla Zunić
November 1977, Psychological medicine,
Armin Skrbo, and Aida Selava, and Lejla Zunić
April 1996, Medical interface,
Armin Skrbo, and Aida Selava, and Lejla Zunić
January 2001, The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique,
Copied contents to your clipboard!